Revolutionizing gene therapy by redefining AAV development status quo

Viral vector-based gene therapies are the frontier of modern medicine. While these therapies hold the promise to cure genetic illnesses through single-dose treatments, current cell-based technology used to produce these complex products is highly unsuitable, posing a major bottleneck to reaching patients. With long development timelines, high costs, and risk of impurities, the industry calls for a quantum leap in process technology. 

Fuse Vectors is a biotech startup revolutionizing gene therapy with its cell-free viral vector technology. They combine component module libraries with an on-demand biocatalytic AAV capsid filling processes to eliminate these bottlenecks, offering significant improvements, reducing production time and costs while ensuring high vector quality to meet patients’ unmet needs. Harnessing the platform technology, Fuse Vectors aims to accelerate gene therapy development through external collaborations and internal pipeline development.

Historically, Fuse has relied on a combination of Excel, Geneious, and home-grown software. With a growing team, these silos become increasingly cumbersome, creating gaps in data capture and management. Seeking to implement a solid data capture and management system for long-term success, the team turned to Benchling. With newfound end-to-end traceability, the ability to track assays, plasmids, proteins, and samples gives managers and leadership the high-level overview they need.

Driven by a vision to catalyze the gene therapy market, Fuse Vectors aims to be the universal solution for all AAV gene therapy development, meeting the unmet needs of patients and expanding the accessibility of gene therapy to a wider range of indications.